日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Pharmacokinetic, pharmacodynamic, and immunogenic rationale for optimal dosing of pegvaliase, a PEGylated bacterial enzyme, in adult patients with phenylketonuria

苯丙酮尿症成人患者中聚乙二醇化细菌酶培格伐利酶最佳剂量的药代动力学、药效学和免疫原性原理

期刊:Cts-Clinical and Translational Science
影响因子:2.8
doi:10.1111/cts.13043
Qi, Yulan; Patel, Gina; Henshaw, Joshua; Gupta, Soumi; Olbertz, Joy; Larimore, Kevin; Harding, Cary O; Merilainen, Markus; Zori, Roberto; Longo, Nicola; Burton, Barbara K; Li, Mingjin; Gu, Zhonghua; Zoog, Stephen J; Weng, Haoling H; Schweighardt, Becky
微生物学
免疫/内分泌
发表日期：2021
文献求助 收藏

A benefit-risk analysis of pegvaliase for the treatment of phenylketonuria: A study of patients' preferences

培伐利司治疗苯丙酮尿症的获益风险分析：一项基于患者偏好的研究

期刊:Molecular Genetics and Metabolism Reports
影响因子:1.9
doi:10.1016/j.ymgmr.2019.100507
SriBhashyam, Sumitra; Marsh, Kevin; Quartel, Adrian; Weng, Haoling H; Gershman, Ari; Longo, Nicola; Thomas, Janet; Zori, Roberto
发表日期：2019
文献求助 收藏

Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials

在3期临床试验中，免疫反应与苯丙酮尿症成人患者接受培伐利酶治疗的疗效和安全性结果之间的关联

期刊:EBioMedicine
影响因子:10.8
doi:10.1016/j.ebiom.2018.10.038
Gupta, Soumi; Lau, Kelly; Harding, Cary O; Shepherd, Gillian; Boyer, Ryan; Atkinson, John P; Knight, Vijaya; Olbertz, Joy; Larimore, Kevin; Gu, Zhonghu; Li, Mingjin; Rosen, Orli; Zoog, Stephen J; Weng, Haoling H; Schweighardt, Becky
免疫/内分泌
发表日期：2018
文献求助 收藏

Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study

戈利木单抗作为疾病修饰抗风湿药物的附加疗法的疗效和安全性：GO-MORE 研究结果

期刊:Annals of the Rheumatic Diseases
影响因子:20.6
doi:10.1136/annrheumdis-2013-203229
Combe, Bernard; Dasgupta, Bhaskar; Louw, Ingrid; Pal, Sarvajeet; Wollenhaupt, Jürgen; Zerbini, Cristiano A F; Beaulieu, Andre D; Schulze-Koops, Hendrik; Durez, Patrick; Yao, Ruji; Vastesaeger, Nathan; Weng, Haoling H
发表日期：2014
文献求助 收藏

Equivalent responses to disease-modifying antirheumatic drugs initiated at any time during the first 15 months after symptom onset in patients with seropositive rheumatoid arthritis

在血清阳性类风湿关节炎患者中，症状出现后15个月内任何时间开始使用改善病情抗风湿药物的疗效相当

期刊:Journal of Rheumatology
影响因子:3.4
doi:10.3899/jrheum.090818
Weng, Haoling H; Ranganath, Veena K; Khanna, Dinesh; Oh, Myungshin; Furst, Daniel E; Park, Grace S; Elashoff, David A; Sharp, John T; Gold, Richard H; Peter, James B; Paulus, Harold E
关节炎
发表日期：2010
文献求助 收藏